Pulmonary arterial hypertension in patient treated for multiple sclerosis with 4-aminopyridine.
Fundam Clin Pharmacol
; 33(1): 127-129, 2019 Feb.
Article
em En
| MEDLINE
| ID: mdl-29956855
ABSTRACT
4-Aminopyridine (4-AP) is a recent treatment indicated to improve walking in patient with multiple sclerosis. We report the first case of pulmonary arterial hypertension (PAH) that we attribute to the use of 4-AP. A 64-year-old woman with multiple sclerosis presented with dyspnea. After excluding other secondary causes of pulmonary hypertension, a diagnosis of severe PAH due to 4-AP was made based on right heart catheterization. History revealed that the dyspnea began with the initiation of 4-AP. After discontinuation of 4-AP therapy and initiation of ambrisentan and tadalafil, dyspnea and pulmonary arterial pressure have improved significantly and one specific PAH treatment was stopped. 4-AP is an outward rectifying potassium channel blocker with a vasoconstrictor effect in animal's pulmonary artery. According to the chronological sequence of events, the lack of other etiology, and its pharmacological plausibility, 4-AP is highly suspected to have induced our patient's PAH.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
4-Aminopiridina
/
Bloqueadores dos Canais de Potássio
/
Hipertensão Pulmonar
/
Esclerose Múltipla
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article